HNN3.0
Register
Register
Register

Project cooperationUpdated on 27 November 2025

New in vitro assay methodologies

Seinor research scientist at SINTEF Industry

Trondheim, Norway

About

To be able to better predict the safety and efficacy of drugs, including advanced therapies (e.g. mRNA therapies, immune therapies), and at the same time account for the requirement for multiple parallel testing and throughput, we are designing 2D and 3D cell models from cell lines, primary cells, stem cells and patient-derived tissues, tailored to specific applications.

We are in particular interested in applying models for sex- and hormone-differentiated screening, to enable prediction of sex- and gender-dependent differences in drug safety and effect.

We have demonstrated ability of our cell models to be used for machine learning model building, as well as for verifying AI-predicted drug effects.

We are looking for: partners with relevant complementary expertise to join consortia and develop project together

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

Organisation

SINTEF Industry

R&D Institution

Trondheim, Norway

Similar opportunities

  • Project cooperation

    Methods to assess sex, hormone, genetic, and physiologic population differences

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Torkild Visnes

    Senior scientist at SINTEF Industry

    Trondheim, Norway

  • Project cooperation

    A Multidisciplinary Biomarker Platform to Determine the Effect of Sex-Specific Hormonal and Epigenetic Factors on Cardiovascular Disease Risk

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Seyma Aydinlik

    Senior researcher at TUBITAK

    KOCAELI, Türkiye

  • Project cooperation

    Mechanisms of sexual dimorphisms

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Nitzan Gonen

    Principal Investigator at Bar Ilan University

    Ramat Gan, Israel